vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Tyler Technologies (TYL). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $613.5M, roughly 1.0× Tyler Technologies). Royalty Pharma plc runs the higher net margin — 34.4% vs 13.2%, a 21.2% gap on every dollar of revenue. On growth, Tyler Technologies posted the faster year-over-year revenue change (8.6% vs 4.8%). Over the past eight quarters, Tyler Technologies's revenue compounded faster (6.5% CAGR vs 4.6%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Tyler Technologies, Inc. is an American technology company based in Plano, Texas, that provides proprietary software to the U.S. public sector. Tyler Technologies has offices in 17 states and one in Toronto, Ontario, Canada.

RPRX vs TYL — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.0× larger
RPRX
$622.0M
$613.5M
TYL
Growing faster (revenue YoY)
TYL
TYL
+3.8% gap
TYL
8.6%
4.8%
RPRX
Higher net margin
RPRX
RPRX
21.2% more per $
RPRX
34.4%
13.2%
TYL
Faster 2-yr revenue CAGR
TYL
TYL
Annualised
TYL
6.5%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RPRX
RPRX
TYL
TYL
Revenue
$622.0M
$613.5M
Net Profit
$214.2M
$81.2M
Gross Margin
48.3%
Operating Margin
62.4%
16.3%
Net Margin
34.4%
13.2%
Revenue YoY
4.8%
8.6%
Net Profit YoY
2.9%
EPS (diluted)
$0.49
$1.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
TYL
TYL
Q1 26
$613.5M
Q4 25
$622.0M
$575.2M
Q3 25
$609.3M
$595.9M
Q2 25
$578.7M
$596.1M
Q1 25
$568.2M
$565.2M
Q4 24
$593.6M
$541.1M
Q3 24
$564.7M
$543.3M
Q2 24
$537.3M
$541.0M
Net Profit
RPRX
RPRX
TYL
TYL
Q1 26
$81.2M
Q4 25
$214.2M
$65.5M
Q3 25
$288.2M
$84.4M
Q2 25
$30.2M
$84.6M
Q1 25
$238.3M
$81.1M
Q4 24
$208.2M
$65.2M
Q3 24
$544.0M
$75.9M
Q2 24
$102.0M
$67.7M
Gross Margin
RPRX
RPRX
TYL
TYL
Q1 26
48.3%
Q4 25
45.5%
Q3 25
47.2%
Q2 25
45.8%
Q1 25
47.3%
Q4 24
43.8%
Q3 24
43.7%
Q2 24
44.0%
Operating Margin
RPRX
RPRX
TYL
TYL
Q1 26
16.3%
Q4 25
62.4%
13.0%
Q3 25
70.1%
16.4%
Q2 25
36.3%
16.0%
Q1 25
94.0%
15.8%
Q4 24
60.9%
13.2%
Q3 24
15.2%
Q2 24
50.2%
14.4%
Net Margin
RPRX
RPRX
TYL
TYL
Q1 26
13.2%
Q4 25
34.4%
11.4%
Q3 25
47.3%
14.2%
Q2 25
5.2%
14.2%
Q1 25
41.9%
14.3%
Q4 24
35.1%
12.1%
Q3 24
96.3%
14.0%
Q2 24
19.0%
12.5%
EPS (diluted)
RPRX
RPRX
TYL
TYL
Q1 26
$1.88
Q4 25
$0.49
$1.50
Q3 25
$0.67
$1.93
Q2 25
$0.07
$1.93
Q1 25
$0.55
$1.84
Q4 24
$0.46
$1.48
Q3 24
$1.21
$1.74
Q2 24
$0.23
$1.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
TYL
TYL
Cash + ST InvestmentsLiquidity on hand
$618.7M
$346.4M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
$3.6B
Total Assets
$19.6B
$4.8B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
TYL
TYL
Q1 26
$346.4M
Q4 25
$618.7M
$1.1B
Q3 25
$938.9M
$950.8M
Q2 25
$631.9M
$892.3M
Q1 25
$1.1B
$807.4M
Q4 24
$929.0M
$768.0M
Q3 24
$950.1M
$544.3M
Q2 24
$1.8B
$258.0M
Total Debt
RPRX
RPRX
TYL
TYL
Q1 26
Q4 25
$9.0B
$599.7M
Q3 25
$8.9B
$599.2M
Q2 25
$8.0B
$598.8M
Q1 25
$7.6B
$598.4M
Q4 24
$7.6B
$597.9M
Q3 24
$7.6B
$597.5M
Q2 24
$7.6B
$597.1M
Stockholders' Equity
RPRX
RPRX
TYL
TYL
Q1 26
$3.6B
Q4 25
$9.7B
$3.7B
Q3 25
$9.6B
$3.6B
Q2 25
$9.5B
$3.6B
Q1 25
$9.8B
$3.5B
Q4 24
$10.3B
$3.4B
Q3 24
$10.3B
$3.3B
Q2 24
$9.8B
$3.1B
Total Assets
RPRX
RPRX
TYL
TYL
Q1 26
$4.8B
Q4 25
$19.6B
$5.6B
Q3 25
$19.3B
$5.5B
Q2 25
$18.3B
$5.4B
Q1 25
$17.6B
$5.2B
Q4 24
$18.2B
$5.2B
Q3 24
$18.0B
$5.0B
Q2 24
$17.7B
$4.8B
Debt / Equity
RPRX
RPRX
TYL
TYL
Q1 26
Q4 25
0.92×
0.16×
Q3 25
0.93×
0.17×
Q2 25
0.84×
0.16×
Q1 25
0.78×
0.17×
Q4 24
0.74×
0.18×
Q3 24
0.74×
0.18×
Q2 24
0.78×
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
TYL
TYL
Operating Cash FlowLast quarter
$827.1M
$107.3M
Free Cash FlowOCF − Capex
$2.0M
FCF MarginFCF / Revenue
0.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.86×
1.32×
TTM Free Cash FlowTrailing 4 quarters
$585.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
TYL
TYL
Q1 26
$107.3M
Q4 25
$827.1M
$243.9M
Q3 25
$702.6M
$255.2M
Q2 25
$364.0M
$98.3M
Q1 25
$596.1M
$56.2M
Q4 24
$742.5M
$224.8M
Q3 24
$703.6M
$263.7M
Q2 24
$658.2M
$64.3M
Free Cash Flow
RPRX
RPRX
TYL
TYL
Q1 26
$2.0M
Q4 25
$239.6M
Q3 25
$251.3M
Q2 25
$92.8M
Q1 25
$53.8M
Q4 24
$221.0M
Q3 24
$260.8M
Q2 24
$57.7M
FCF Margin
RPRX
RPRX
TYL
TYL
Q1 26
0.3%
Q4 25
41.7%
Q3 25
42.2%
Q2 25
15.6%
Q1 25
9.5%
Q4 24
40.8%
Q3 24
48.0%
Q2 24
10.7%
Capex Intensity
RPRX
RPRX
TYL
TYL
Q1 26
Q4 25
0.8%
Q3 25
0.7%
Q2 25
0.9%
Q1 25
0.4%
Q4 24
0.7%
Q3 24
0.5%
Q2 24
1.2%
Cash Conversion
RPRX
RPRX
TYL
TYL
Q1 26
1.32×
Q4 25
3.86×
3.72×
Q3 25
2.44×
3.02×
Q2 25
12.06×
1.16×
Q1 25
2.50×
0.69×
Q4 24
3.57×
3.45×
Q3 24
1.29×
3.47×
Q2 24
6.45×
0.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

TYL
TYL

Subscriptions$429.7M70%
Maintenance$108.9M18%
Other$74.9M12%

Related Comparisons